GSC
LSTA icon

Ground Swell Capital’s Lisata Therapeutics LSTA Stock Holding History

Ground Swell Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-38,987
Closed -$72.5K – 151
2025
Q4 		$72.5K Buy
38,987
+15,213
+64% +$33.8K 0.15% 51
2025
Q3 		$62.3K Buy
+23,774
New +$59.6K 0.14% 99

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Ground Swell Capital's LSTA Position: Q1 2026 in Review

Ground Swell Capital sold out of Lisata Therapeutics (LSTA) in Q1 2026, closing a stake of 38,987 shares — an estimated $72.5K sold.

Ground Swell Capital first reported a position in LSTA in Q3 2025 and held it in 2 quarters. The position peaked at $72.5K in Q4 2025. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Ground Swell Capital reported no remaining Lisata Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ground Swell Capital sold 38,987 Lisata Therapeutics shares in Q1 2026, an estimated $72.5K.
  • Ground Swell Capital first reported a position in Lisata Therapeutics in Q3 2025 and held it in 2 quarters.
  • Ground Swell Capital's Lisata Therapeutics position peaked at $72.5K in Q4 2025.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Ground Swell Capital's 13F filing for Q1 2026, filed 21 Apr 2026.